The announcement of the first quarter results of 2022 will be disclosed soon!

Entering March, listed companies have successively disclosed their annual results for 2021.
At the same time, some companies have also released their first quarter results in 2022
.
Among them, in the pharmaceutical industry, a number of pharmaceutical companies have recently released their 2022 first quarter performance forecasts, including Zuoli Pharmaceuticals and WuXi AppTec
.
On March 9, Zuoli Pharmaceutical released an announcement on the pre-increase in the first quarter of 2022.
It is expected that from January 1, 2022 to March 31, 2022, it will achieve a net profit of 67 million to 71 million yuan, an increase of 52.
98% to 62.
12%
.
In the same period of last year, the company realized a net profit of 43.
7953 million yuan
.
Regarding the reasons for the changes in performance, the company stated that the main reason is that during the reporting period, the operating income of the company's main products Wuling Capsules, Bailing Tablets and Lingze Tablets all achieved rapid growth
.
In addition, during the reporting period, with the improvement of the company's profitability, the company's funds were more abundant, the loan scale was reduced, and the financial expenses were lower than the same period last year
.
According to the data, Zuoli Pharmaceutical is an enterprise integrating scientific research, production and sales
.
The company has modern production lines for raw materials, extraction, tablets, capsules, decoction pieces, granules, etc.
, based on the bio-fermentation technology of medicinal fungi to produce modern biological traditional Chinese medicine products, currently mainly engaged in medicinal fungi Wuling and Bailing series products, traditional Chinese medicine Research and development, production and sales of decoction pieces and traditional Chinese medicine granules
.
In recent years, traditional Chinese medicine has been supported by a series of favorable policies, and the industry of traditional Chinese medicine decoction pieces and traditional Chinese medicine formula granules has also ushered in good development opportunities
.
It is reported that Zuoli Pharmaceutical took the initiative to seize the opportunity, and three core products have entered the National Essential Drug List
.
At the same time, the company is committed to seizing the opportunity of Internet-based medical care and retail, building an Internet marketing platform for the entire Chinese medicine industry chain, and gradually exploring the layout of new channel businesses such as Internet + medical care and e-commerce
.
The company's operating income in 2021 is 1.
457 billion yuan, an increase of 33.
60% over the same period of the previous year; the net profit is 179 million yuan, an increase of 101.
28% over the same period of the previous year
.
Also on the 9th, WuXi PharmaTech announced its main operating data from January to February 2022.

.
The data shows that from January to February 2022, the company's orders in hand and sales revenue increased by more than 65% year-on-year, hitting a record high, mainly due to the continuous development of the company's integrated CRDMO and CTDMO businesses
.
In addition, the company expects revenue growth of 65% to 68% year over year in the first quarter of 2022
.
Looking ahead to the full year, the company's revenue growth is expected to reach 65% to 70% year over year
.
According to the data, WuXi AppTec is a drug R&D service platform.
The company's R&D services cover chemical drug R&D and production, cell and gene therapy R&D and production, and medical device testing
.
At present, WuXi AppTec has established cooperative R&D relationships with more than 4,400 companies and other entities in more than 30 countries around the world
.
It is understood that in the CRO industry to which WuXi AppTec belongs, in recent years, under the background of the rapid development of innovative drugs, the market demand is constantly expanding, and the industry is booming.
As a giant, WuXi AppTec has performed well
.
The 2021 performance report shows that the company's revenue in 2021 is 22.
902 billion yuan, a year-on-year increase of 38.
5%; the net profit attributable to shareholders of listed companies is 5.
097 billion yuan, a year-on-year increase of 72.
19%
.
In addition to the sharp rise in performance, WuXi AppTec's stock price has also risen all the way
.
From the low price of the company's stock price of 10.
27 yuan when it was listed in 2018, by July 2021, its stock price had risen to 172.
49 yuan, an increase of more than 15 times
.
In addition, a group of pharmaceutical companies recently expected to achieve performance growth in the first quarter of 2022
.
For example, Sannuo Bio has been busy with production lines since the start of construction this year.
The company expects that sales in the first quarter of this year will increase by 20% year-on-year; Huitai Medical recently released an announcement on the main operating data from January to February 2022.
As of February, the company achieved a total operating income of about 156 million yuan, a year-on-year increase of about 70%
.
On the whole, the pharmaceutical companies that have released the first quarter performance forecast for 2022 are basically in the high-prosperity track, such as traditional Chinese medicine, CXO, testing, etc.

.
The industry believes that these sub-sectors have a certain room for growth and have great market potential
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.